Legacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical Drugs

RegulatoryPositive

AI Analysis

Summary

Legacy Healthcare welcomes the proposed "ADVANCING BOTANICAL DRUG DEVELOPMENT ACT OF 2026" introduced on August 27, 2026, which would grant 12-year post-approval market exclusivity for FDA-regulated botanical drugs to incentivize innovation and investment.

Outcome Details

Congressional legislation proposed to provide 12-year post-approval market exclusivity for FDA-approved botanical drugs

Importance:5/10

Sentiment:

0.60

regulatorybotanical drugsmarket exclusivitycongressional legislationFDA

Related Companies

$HR

Read the original article

Published by PR Newswire Biotech on September 3, 2026 12:15 PM

Read Original